Chinook Therapeutics Acquisition Finalizes Novartis Expansion into Kidney Disease Market

The independent trading journey of Chinook Therapeutics shares has concluded. In a strategic move finalized in August 2023, the biotechnology firm was fully acquired by pharmaceutical giant Novartis. Shareholders of the former company received a cash payment of $40 per share, marking the end of Chinook’s tenure as a publicly traded entity.

The acquisition was driven by Novartis’s strategic objective to bolster its presence in the nephrology treatment sector. Chinook’s valuable pipeline, featuring late-stage development products for rare kidney conditions, presented a compelling opportunity. The boards of directors from both organizations gave their unanimous approval for the transaction.

Under the terms of the agreement, Novartis completed the purchase Read more...